Project Grant R01HL175964
Award Date
7/1/24
Completion Date
6/30/28
Dollars Obligated
$719K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This Project Grant award for $2,507,438.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to perform a deep mutational scan of the MYH7 gene in human induced pluripotent stem cell-derived cardiomyocytes. The goal is to determine the functional consequences of nearly all possible single nucleotide variants in MYH7, a gene associated with hypertrophic cardiomyopathy, in order to assist with clinical...
This $756,039 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to understand the impact of regulatory genetic variants on the severity of cardiomyopathies caused by haploinsufficiency genes, such as MYBPC3 and DSP. The 5-year project, led by researchers at the University of Michigan, will use human induced pluripotent stem cell cardiomyocytes and mouse models to quantify the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to identify pathogenic variants and factors influencing variable expressivity of hypertrophic cardiomyopathy (HCM). The $126,306 award, with a period of performance from December 2024 to November 2026, will enable the University of Washington to establish a high-throughput system using human induced pluripotent stem...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $2,044,805 to Case Western Reserve University to advance the understanding of molecular mechanisms underlying genetic cardiac myosin binding protein C (cMyBP-C) cardiomyopathies. The 4-year research project integrates experimental approaches across molecular biology, biophysics, animal physiology, and computer modeling to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to define the effects of cardiac myosin binding protein C (cMyBP-C) missense variants on cardiac sarcomere structure and function, and link these mechanisms to the development of hypertrophic cardiomyopathy (HCM). The $730,764 award to Case Western Reserve University, spanning from June 1, 2025, to March 31, 2029, will utilize a comprehensive...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,185,454 to Tufts Medical Center to investigate the role of the FHOD3 gene variant in regulating the autophagy pathway and its impact on the development of hypertrophic cardiomyopathy (HCM) and heart failure. The research aims to evaluate the effects of stimulating or inhibiting autophagy in FHOD3 variant mice, as well as assessing...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The key products and services to be delivered include: Using high-throughput CARDIO and Perturb-seq assays, the project will analyze the impact of loss of genes associated with heart failure risk through morphological...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will investigate a novel signaling pathway, the Hippo-YAP pathway, to develop new treatments for heart failure. The primary awardee, Baylor College of Medicine, will receive $693,261 to gain insights into gene therapy strategies that knock down Hippo signaling in cardiac tissue following myocardial infarction. The central...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $756,895 to Duke University to develop, validate, and determine the clinical utility of a precision genetic testing approach guided by machine learning (ML) algorithms. The objective is to enhance the diagnosis of hypertrophic cardiomyopathy (HCM) and transthyretin amyloidosis (ATTR-CM), which are rare but common in aggregate, through the integration of ML-based...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $802,762 to The University of Texas Southwestern Medical Center to conduct research on interpreting the impact of genetic variants, both coding and non-coding, on congenital heart disease. The research aims to define cardiac gene regulatory networks, characterize genetic variants that regulate cardiac gene programs, and assess the...